Evaluation of the Bioavailability of Pramlintide

Completed · Phase 2

Conditions studied: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2

In brief

This is a randomized, open-label, crossover study to examine the bioavailability of pramlintide in normal weight and overweight subjects with type 1 and type 2 diabetes mellitus using insulin.

Key facts

Study ID

NCT00042471

Run by

AstraZeneca

People needed

75

Starts

2002-06-01

Expected to finish

2002-12-01

Last updated by the study team

2015-09-23

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HbA1c value between 6-12%
• BMI <= 27 kg/m2 or BMI >=30 to <= 45 kg/m2
• Consistent insulin regimen for 2 months prior to screening

Where it is running

• Orlando Clinical Research Center — Orlando, Florida, United States
• New Orleans Center for Clinical Research — New Orleans, Louisiana, United States
• DaVita Clinical Research — Minneapolis, Minnesota, United States
• CEDRA Clinical Research, LLC — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.